Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 9.72
- Piotroski Score 1.00
- Grade Buy
- Symbol (LRMR)
- Company Larimar Therapeutics, Inc.
- Price $6.14
- Changes Percentage (0.9%)
- Change $0.06
- Day Low $5.68
- Day High $6.29
- Year High $13.68
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/12/2025
- Fiscal Year End N/A
- Average Stock Price Target $22.00
- High Stock Price Target $25.00
- Low Stock Price Target $14.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.96
- Trailing P/E Ratio -9.99
- Forward P/E Ratio -9.99
- P/E Growth -9.99
- Net Income $-36,949,000
Income Statement
Quarterly
Annual
Latest News of LRMR
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth
Larimar Therapeutics' stock has surged 170% in the last year, despite being an unprofitable business. With a strong cash position and low cash burn relative to market cap, the company seems well-equip...
By Yahoo! Finance | 1 month ago
